Chronic low back pain remains one of the leading causes of disability worldwide, yet its underlying neurobiological mechanisms are poorly understood. The current study led by Pan, Shen, Abatan, and colleagues employed male mouse models to elucidate how osteoclasts—bone-resorbing cells at the spinal endplates—initiate a pathological cascade that sustains pain hypersensitivity without ongoing tissue injury.

The team identified that increased osteoclast activity at the vertebral endplates elevates the expression of the Netrin-1 receptor DCC within the dorsal horn neurons of the spinal cord. DCC is traditionally known for its role in neural development and axonal guidance, but here it forms a positive feedback loop that amplifies pain signaling. This amplification loop enhances nociceptive neuronal excitability, driving persistent pain perception even in the absence of new peripheral damage.

Mechanistically, osteoclast-derived signals enhance DCC expression and activation in excitatory dorsal horn neurons, which in turn augment synaptic transmission and facilitate central sensitization—key hallmarks of nociplastic pain. This feedback loop was shown to maintain a sustained state of dorsal horn hyperexcitability, generating chronic low back pain phenotypes in the mouse model.

Importantly, pharmacological or genetic disruption of DCC signaling within the dorsal horn effectively broke the amplification loop, reversing hypersensitivity and reducing nociplastic pain responses. These interventions offer promising avenues for targeting central pain processing mechanisms rather than the peripheral pain sources, representing a paradigm shift in chronic pain therapeutics.

The study also links osteoclast activity with central nervous system plasticity, bridging two previously disconnected fields: bone metabolism and neural pain circuitry. This cross-disciplinary insight suggests that aberrant osteoclast function at spinal sites not only contributes to structural degeneration but actively drives maladaptive pain signaling cascades.

Given the complexity and heterogeneity of chronic low back pain in patients, these findings open new paths for precision medicine. Identifying biomarkers of osteoclast activity or dorsal horn DCC dynamics could help stratify patients who might benefit from therapies aimed at interrupting this novel amplification loop.

This innovative research underscores the importance of central nervous system targets in chronic nociplastic pain and challenges the existing framework that centers on peripheral tissue damage as a sole driver. By dissecting the molecular dialogue between bone-resorbing cells and spinal neurons, the study sets the stage for next-generation treatments combating one of the most prevalent and debilitating conditions globally.

As investigations continue, it is hoped that therapeutic strategies derived from this mechanism might alleviate the suffering of millions, improving quality of life and reducing healthcare burdens associated with chronic low back pain.

Subject of Research: Mechanisms of chronic nociplastic low back pain involving dorsal horn DCC signaling and osteoclast activity.

Article Title: Dorsal horn DCC amplification loop induced by endplate osteoclasts generates chronic nociplastic low back pain in male mice.

Article References:
Pan, D., Shen, M., Abatan, E. et al. Dorsal horn DCC amplification loop induced by endplate osteoclasts generates chronic nociplastic low back pain in male mice. Nat Commun (2026). https://doi.org/10.1038/s41467-026-75423-9

Image Credits: AI Generated

At the heart of this study is the parathyroid hormone (PTH), a key regulator of calcium metabolism and bone turnover, long employed clinically to counteract osteoporosis through its bone-forming actions. Surprisingly, increasing evidence now suggests PTH’s role transcends skeletal maintenance, extending into modulation of sensory nerve growth and pain perception. The Johns Hopkins team, led by Dr. Janet L. Crane, embarked on an intricate exploration of spinal degeneration models in mice, keen to elucidate how PTH influences aberrant nerve fiber proliferation within compromised vertebral endplates—critical anatomical structures that interface spinal discs and vertebrae.

Spinal degeneration provokes an abnormal innervation pattern whereby nociceptive (pain-sensing) nerve fibers invade regions previously devoid of such neural elements. This pathological nerve ingrowth heightens pain sensitivity, aggravating chronic low back pain symptoms. Utilizing three robust mouse models that simulate aging-related degeneration, surgically induced instability, and genetic predisposition, the researchers administered daily injections of synthetic PTH over periods ranging from two weeks to two months. High-resolution imaging coupled with behavioral assays measuring responses to pressure, thermal stimuli, and locomotor activity provided comprehensive evaluation of treatment effects.

Remarkably, PTH-treated mice exhibited a restoration of vertebral endplate integrity, characterized by reduced porosity and enhanced structural stability. These anatomical improvements translated functionally into diminished pain behaviors: treated animals showed increased tolerance to mechanical pressure, delayed withdrawal from heat stimuli, and higher levels of spontaneous physical activity compared to untreated controls. Such findings underscore a tangible reversal of degenerative changes contributing to pain.

Delving deeper, the investigative team uncovered that PTH exerts its neuromodulatory effects by stimulating osteoblasts—the bone-forming cells—to secrete Slit3, a repulsive guidance protein known to regulate axon pathfinding. Slit3 acts as a molecular barrier deterring nociceptive nerve fibers from aberrantly infiltrating the vertebral endplate microenvironment. In vitro assays confirmed Slit3’s capacity to truncate nerve extensions and suppress invasive behaviors, lending mechanistic credence to the in vivo observations.

Moreover, the genetic ablation of Slit3 specifically in osteoblasts abolished PTH’s capacity to mitigate abnormal sensory innervation and alleviate pain-related manifestations in the murine models. This critical evidence delineates a PTH-osteoblast-Slit3 signaling axis essential for modulating pathological nerve growth in degenerative spine conditions. Further molecular analysis identified FoxA2, a transcription factor instrumental in activating Slit3 gene expression in response to PTH signaling, elucidating part of the intracellular machinery converting hormonal cues into extracellular guidance signals.

While these insights derive from animal experiments, their translational potential is profound. Notably, anecdotal clinical observations have reported decreased back pain among osteoporosis patients undergoing PTH therapy, an effect now attributable to the neuro-osteogenic mechanisms illuminated by this study. This paradigm shift advocates PTH not merely as a bone anabolic agent but as a novel modulator capable of curbing chronic pain through restraining pathological nerve sprouting.

Cautiously, Dr. Crane and colleagues emphasize the necessity for rigorous clinical trials to evaluate safety, dosing, and efficacy parameters in human populations before integrating PTH-based regimens into standard care for low back pain associated with spinal degeneration. Nevertheless, the prospect of repurposing a well-characterized hormone with established pharmacology holds promise for addressing an unmet medical need, potentially transforming management strategies for millions afflicted by chronic spinal pain.

This research not only advances our fundamental comprehension of skeletal-pain neurobiology but also catalyzes future endeavors in drug development targeting the neurochemical microenvironment within degenerating musculoskeletal interfaces. By illuminating the reversible nature of aberrant nerve innervation governed by osteoblast-derived cues, the findings pave the way for innovative interventions capable of halting or even reversing the disabling effects of spinal degeneration.

In summary, this pioneering study reveals that parathyroid hormone triggers osteoblast secretion of Slit3, which repels invading pain-sensing nerve fibers within degenerated vertebral endplates, thereby restoring spinal tissue integrity and alleviating chronic low back pain in mice. The intricate interplay between hormonal regulation, bone cell signaling, and nerve growth modulation presents a compelling therapeutic avenue that merits expedited exploration in human clinical contexts.

These advances epitomize the potential of integrative biomedical research to decipher complex disease mechanisms and translate them into tangible health benefits, offering renewed hope for patients burdened by chronic pain conditions historically deemed refractory to treatment.

Subject of Research: Animals

Article Title: PTH induced osteoblast Slit3 to decrease aberrant sensory innervation in degenerated vertebral endplates to relieve low back pain in mice

News Publication Date: 22-Jan-2026

References: DOI: 10.1038/s41413-025-00488-z

Image Credits: PlanetSupplement from Openverse

Keywords: Back pain, Hormone therapy, Aging populations, Skeleton, Nervous system, Musculoskeletal system, Chronic pain, Osteoporosis, Diseases and disorders, Animal models